Patents by Inventor Julien Balzeau

Julien Balzeau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF A NEUROFILAMENT PEPTIDE FOR THE TREATMENT OF GLIOMA
    Publication number: 20170000846
    Abstract: The present invention provides a new drug to treat malignant glioma, which is the most prevalent type of primary tumor of the central nervous system (CNS). The present invention indeed shows that the isolated NFL-TBS40-63 peptide is highly specific for glioma cells, in which it triggers apoptosis. It is therefore presented here for use in a method for treating malignant glioma. The present invention further relates to the use of the NFL-TBS40-63 peptide for detecting specifically glioma cells either in vivo, or in vitro, or for addressing chemical compounds to said tumor cells.
    Type: Application
    Filed: August 5, 2016
    Publication date: January 5, 2017
    Applicants: UNIVERSITE D'ANGERS, INSTITU NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY
    Inventors: Joel Eyer, Alan Peterson, Julien Balzeau, Raphael Berges
  • Use of a neurofilament peptide for the treatment of glioma
    Patent number: 9446092
    Abstract: The present invention provides a new drug to treat malignant glioma, which is the most prevalent type of primary tumor of the central nervous system (CNS). The present invention indeed shows that the isolated NFL-TBS40-63 peptide is highly specific for glioma cells, in which it triggers apoptosis. It is therefore presented here for use in a method for treating malignant glioma. The present invention further relates to the use of the NFL-TBS40-63 peptide for detecting specifically glioma cells either in vivo, or in vitro, or for addressing chemical compounds to said tumor cells.
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: September 20, 2016
    Assignees: UNIVERSITE D'ANGERS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY
    Inventors: Joël Eyer, Alan Peterson, Julien Balzeau, Raphaël Berges
  • USE OF A NEUROFILAMENT PEPTIDE FOR THE TREATMENT OF GLIOMA
    Publication number: 20130004429
    Abstract: The present invention provides a new drug to treat malignant glioma, which is the most prevalent type of primary tumor of the central nervous system (CNS). The present invention indeed shows that the isolated NFL-TBS40-63 peptide is highly specific for glioma cells, in which it triggers apoptosis. It is therefore presented here for use in a method for treating malignant glioma. The present invention further relates to the use of the NFL-TBS40-63 peptide for detecting specifically glioma cells either in vivo, or in vitro, or for addressing chemical compounds to said tumor cells.
    Type: Application
    Filed: December 14, 2010
    Publication date: January 3, 2013
    Inventors: Joël Eyer, Alan Peterson, Julien Balzeau, Raphaël Berges